Your browser doesn't support javascript.
loading
Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens.
Frias, Juan Pablo; Nauck, Michael A; Van, Joanna; Benson, Charles; Bray, Ross; Cui, Xuewei; Milicevic, Zvonko; Urva, Shweta; Haupt, Axel; Robins, Deborah A.
Afiliação
  • Frias JP; National Research Institute, Los Angeles California, United States.
  • Nauck MA; Diabetes Center Bochum-Hattingen, St Josef Hospital, Ruhr-University Bochum, Bochum, Germany.
  • Van J; Diabetes Research Center, Tustin, California.
  • Benson C; Eli Lilly and Company, Indianapolis, Indiana.
  • Bray R; Eli Lilly and Company, Indianapolis, Indiana.
  • Cui X; Eli Lilly and Company, Indianapolis, Indiana.
  • Milicevic Z; Eli Lilly and Company, Vienna, Austria.
  • Urva S; Eli Lilly and Company, Indianapolis, Indiana.
  • Haupt A; Eli Lilly and Company, Indianapolis, Indiana.
  • Robins DA; Eli Lilly and Company, Indianapolis, Indiana.
Diabetes Obes Metab ; 22(6): 938-946, 2020 06.
Article em En | MEDLINE | ID: mdl-31984598
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Limite: Aged / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Limite: Aged / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article